This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite

Starlynn Clarke, Ph.D.
Director of Preclinical Biology at Rondo Therapeutics


Starlynn Clarke leads the preclinical biology group at Rondo Therapeutics, an IO-focused biopharmaceutical company developing innovative bispecific therapeutic antibodies for treating solid tumors. Starlynn has worked in discovery and preclinical development in the fields of oncology and immunology at several biotechnology start-up companies, including Frontier Medicines and Caribou Biosciences. As a founding member of the preclinical biology team at Teneobio, a highly successful multispecific therapeutic antibody company, she contributed to several bispecific antibody programs currently in clinical trials. Starlynn completed her PhD in the lab of Charles Craik at UCSF, where she studied novel viral and fungal host-pathogen interactions.

Agenda Sessions

  • Co-stimulatory Bispecific Antibody Strategies for Treating Solid Tumors